FIELD: pharmaceutical industry.
SUBSTANCE: invention relates to the preparation and use in the pharmaceutical industry of crystalline levoisovaleril spiramycin II of formula (I):
characterized by the melting point of 120–128 °C and X-ray diffraction, measured using Cu-K radiationα with peaks at 2θ = 10.0°, 11.6°, 16.4°, 17.3°, 19.1°, 21.2°, 22.1°, 22.7°, 26.4°, 26.9°, 27.5° and 31.5°, whereby dissolving said crystalline compound in chloroform at 25 °C and a concentration of 0.02 g/ml optical rotation angle [α]D is -55° – 61°. A method for the preparation of said crystalline compound comprises dissolving the solid levoisovaleril spiramycin II in a mixture of absolute methyl alcohol, anhydrous acetone and absolute ethyl alcohol in a ratio of 1: 0.1–10:0.5–1, adding distilled water with stirring, cooling to 5–15 °C to obtain the said crystallographic compound of levoisovaleril spiramycin II.
EFFECT: new effective method of obtaining a new crystalline form is introduced, suitable for the effective preparation of drug anti-infectious agents is proposed.
19 cl, 5 dwg, 56 ex, 10 tbl
Title |
Year |
Author |
Number |
LEVOROTATORY ISOVALERYLSPIRAMYCIN 1, II, III, PREPARATIONS, METHOD FOR PREPARATION AND USE |
2011 |
|
RU2593498C2 |
DOSAGE FORM LEVOCARRIMYCIN, METHOD FOR PRODUCTION AND USE THEREOF |
2011 |
|
RU2593499C2 |
LEVOYSOVALERIL SPIRAMYCIN III, PREPARATIONS, METHOD OF PREPARATION AND USE |
2011 |
|
RU2647237C1 |
RAPAMYCIN TARGET INHIBITOR IN MAMMALIAN CELLS, PHARMACEUTICAL COMPOSITION AND USE THEREOF |
2019 |
- Ksia, Mingyu
- Zhao, Ksiaofeng
- Dzhiang, Ksyunlej
- Dzhiang, Ksyundong
|
RU2768583C2 |
USE OF CARRIMYCIN OR ITS ACTIVE INGREDIENTS |
2019 |
- Ksia, Mingyu
- Zhao, Ksiaofeng
- Dzhiang, Ksyunlej
- Dzhiang, Ksyundong
|
RU2771046C2 |
USE OF ISOVALERYL-SPIRAMYCIN I, II AND/OR III IN MANUFACTURE OF DRUG FOR TREATMENT AND/OR PREVENTION OF TUMOR AND PREPARATION OF DRUG |
2018 |
- Dzhiang, Enkhong
- Khe, Vejking
- Dai, Dzhianlyu
- Dzhiang, Yang
- Dzhiang, Ksyunlej
- Zhao, Ksiaofeng
|
RU2766176C2 |
THE USE OF CARRIMYCIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PRODUCTION OF MEDICINES FOR TREATMENT AND / OR TUMOR PREVENTION |
2018 |
- Dzhiang, Enkhong
- Ksia, Mingyu
- Dzhiang, Ksyunlej
- Dzhiang, Ksyundong
|
RU2746047C1 |
BIOSYNTHETIC GENE CLUSTER OF CARRIMYCIN |
2016 |
- Vang Yuiguang
- Dzhang Yang
- Zhao Ksiaofeng
- Khe Vejking
- Dai Dzhianlu
|
RU2719189C2 |
METHOD FOR USING CARRIMYCIN AGAINST INFECTION RESISTANCE INDUCED BY MYCOBACTERIUM TUBERCULOSIS |
2016 |
- Vang Yuiguang
- Dzhang Yang
- Zhao Ksiaofeng
- Khao Vejking
|
RU2733382C2 |
METHOD OF OBTAINING PENICILLIN DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS (VERSIONS) |
0 |
- Khirosi Isikava
- Fudzio Tabusa
- Kazuyuki Nakagava
|
SU1151212A3 |